Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

Published byFrank Blake Modified over 5 years ago

Similar presentations

Presentation on theme: "A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts."— Presentation transcript:

1 A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts

2 C Effect of GO on relapse stratified by CD33 expression on CD34+ blasts D Effect of GO dose on relapse stratified by CD33 expression on CD34+ blasts Supplementary Figure S8 Pre-treatment CD33 expression levels on CD34+blasts and response to GO in AML patients Forest plot analysis showing effect of CD33 expression on survival (A-B) and relapse (C-D). Response to GO in (A,C) non-CBF patients (younger and older) and in (B,D) GO dose randomisation in younger (NCRI-AML17) patients.

Download ppt "A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts."

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.

Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
Unit Test Practice Algebra 2 Unit Q1: Solve for y. 4y + 6 = 18 a) c) a) c) b)d) b)d) 12 24 3 6.

Unit Test Practice Algebra 2 Unit Q1: Solve for y. 4y + 6 = 18 a) c) a) c) b)d) b)d)
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.

FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.
Hosted by Ms. Williams 100 200 400 300 400 Properties of Quadrilaterals Properties of Parallelograms Properties of Trapezoids Similar Quadrilaterals.

Hosted by Ms. Williams Properties of Quadrilaterals Properties of Parallelograms Properties of Trapezoids Similar Quadrilaterals.
Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.

Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.
Supplementary Figure 1. Outline of the MRC UKALL 2003 trial protocol detailing drugs used and timing schedules for the three regimens. Patients were allocated.

Supplementary Figure 1. Outline of the MRC UKALL 2003 trial protocol detailing drugs used and timing schedules for the three regimens. Patients were allocated.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.
5x + 7 = 47 X = 8. d = ac - 20 Express in Scientific Notation.

5x + 7 = 47 X = 8. d = ac - 20 Express in Scientific Notation.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.

P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.
3-2 Properties of Parallel Lines. 2) Postulate 10: Corresponding Angles Postulate If two parallel lines are cut by a transversal then the pairs of corresponding.

3-2 Properties of Parallel Lines. 2) Postulate 10: Corresponding Angles Postulate If two parallel lines are cut by a transversal then the pairs of corresponding.
Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.
Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12
S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.
  TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

  TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson
Ann Intern Med. 2005;143(6): doi: / Figure Legend: Flow of evidence.

Ann Intern Med. 2005;143(6): doi: / Figure Legend: Flow of evidence.
Volume 383, Issue 9928, Pages (May 2014)

Volume 383, Issue 9928, Pages (May 2014)
Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.

Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.

Similar presentations

Ads by Google